Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hospital Suppliers Show Vigor In ’07, With Prospects Strong For ’08 – Index

This article was originally published in The Gray Sheet

Executive Summary

Baxter and Becton Dickinson were among large-cap hospital supply firms to prove that boring can be beautiful in 2007, as med-tech investors turned off by volatility in the sexier cardiac implant sector turned on to the relative stability of diversified, low-risk hospital products with respectable growth

You may also be interested in...



Endeavor Stent’s Debut Drives 22% Growth In Medtronic Cardiovascular Biz

Medtronic's Endeavor zotarolimus-eluting coronary stent captured over 20% of the U.S. drug-eluting stent market by the tail end of the firm's fiscal fourth quarter (ended April 25), the company reported May 20

Endeavor Stent’s Debut Drives 22% Growth In Medtronic Cardiovascular Biz

Medtronic's Endeavor zotarolimus-eluting coronary stent captured over 20% of the U.S. drug-eluting stent market by the tail end of the firm's fiscal fourth quarter (ended April 25), the company reported May 20

Abbott’s Xience Stent Drives 35% Growth In Overseas Vascular Sales

Abbott continues to look forward to U.S. approval of its Xience V everolimus-eluting coronary stent by the end of June as European adoption of the device drives growth in its vascular unit

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT025655

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel